Perioperative management of severe factor VII deficiency: a single-center experience in China.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Frontiers in Medicine Pub Date : 2025-09-22 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1673206
Chao Zhu, Jinxia Zhao, Longqiang Xu, Wenfei Lu, Shiguo Liu, Jialiang Guan
{"title":"Perioperative management of severe factor VII deficiency: a single-center experience in China.","authors":"Chao Zhu, Jinxia Zhao, Longqiang Xu, Wenfei Lu, Shiguo Liu, Jialiang Guan","doi":"10.3389/fmed.2025.1673206","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inherited factor VII (FVII) deficiency is a rare autosomal recessive disorder whose clinical phenotypes are highly variable. Many studies have observed the absence of a clear-cut and consistent correlation between bleeding symptoms and FVII levels. Perioperative bleeding is a major concern in patients with FVII deficiency, but validated recommendations about the perioperative management of replacement therapy (RT) with FVII are lacking.</p><p><strong>Methods: </strong>Our study retrospectively summarized and analyzed the perioperative hemostasis management of severe FVII deficiency in 20 patients.</p><p><strong>Results: </strong>We found that replacement therapy is generally effective and that there is no significant correlation between the perioperative hemorrhagic complications after RT and the severity of FVII level before RT. Through multivariate statistical analysis and a retrospective analysis of other coagulation factor deficiencies at our center, we found that postoperative secondary hyperfibrinolysis in patients with FVII deficiency may not be universal.</p><p><strong>Discussion: </strong>Antifibrinolytic treatment may be necessary for patients undergoing surgery at sites with high fibrinolytic activity during the perioperative period. In addition, clinical data such as bleeding phenotype, bleeding history, and surgical sites should be given appropriate attention in perioperative treatment and monitoring.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1673206"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497768/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1673206","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Inherited factor VII (FVII) deficiency is a rare autosomal recessive disorder whose clinical phenotypes are highly variable. Many studies have observed the absence of a clear-cut and consistent correlation between bleeding symptoms and FVII levels. Perioperative bleeding is a major concern in patients with FVII deficiency, but validated recommendations about the perioperative management of replacement therapy (RT) with FVII are lacking.

Methods: Our study retrospectively summarized and analyzed the perioperative hemostasis management of severe FVII deficiency in 20 patients.

Results: We found that replacement therapy is generally effective and that there is no significant correlation between the perioperative hemorrhagic complications after RT and the severity of FVII level before RT. Through multivariate statistical analysis and a retrospective analysis of other coagulation factor deficiencies at our center, we found that postoperative secondary hyperfibrinolysis in patients with FVII deficiency may not be universal.

Discussion: Antifibrinolytic treatment may be necessary for patients undergoing surgery at sites with high fibrinolytic activity during the perioperative period. In addition, clinical data such as bleeding phenotype, bleeding history, and surgical sites should be given appropriate attention in perioperative treatment and monitoring.

严重因子七缺乏症围手术期治疗:中国单中心经验
遗传因子VII (FVII)缺乏症是一种罕见的常染色体隐性遗传病,其临床表型变化很大。许多研究观察到出血症状和FVII水平之间缺乏明确和一致的相关性。围手术期出血是FVII缺乏患者的主要问题,但关于FVII替代疗法(RT)围手术期管理的有效建议尚缺乏。方法:回顾性总结分析20例严重FVII缺乏患者的围手术期止血处理。结果:我们发现替代治疗普遍有效,RT后围手术期出血并发症与RT前FVII水平严重程度无显著相关性。通过多因素统计分析和我们中心其他凝血因子缺乏的回顾性分析,我们发现FVII缺乏患者术后继发性高纤溶可能并不普遍。讨论:围手术期在高纤溶活性部位接受手术的患者可能需要抗纤溶治疗。此外,围手术期的治疗和监测应重视出血表型、出血史、手术部位等临床资料。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信